心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：evolocumab对动脉粥样硬化患者认知功能的影响

2020-05-07 MedSci原创 MedSci原创

心血管动脉粥样硬化认知功能
关注

FOURIER临床试验结果显示添加到他汀类药物中的evolocumab不会影响患者的认知功能。本研究通过自我调查描述了整个FOURIER试验中患者报告的认知。

FOURIER临床试验结果显示添加到他汀类药物中的evolocumab不会影响患者的认知功能。本研究通过自我调查描述了整个FOURIER试验中患者报告的认知。

FOURIER是一项随机、双盲、安慰剂对照试验，涉及接受了他汀类药物治疗的动脉粥样硬化性心血管疾病和低密度脂蛋白胆固醇（LDL-C）水平≥70mg/dl或非高密度胆固醇≥100mg/dl的患者。在最后一次访视中，患者完成了一项23个项目的日常认知（ECog）量表中关于记忆和执行领域的调查。最终共有22655名患者完成了ECog调查，在研究结束时，安慰剂组和evolocumab组报告认知功能下降（ECog评分≥2）的患者比例相似（P=0.62）。

研究结果显示，在动脉粥样硬化性心血管疾病患者中，在最大耐受的他汀类药物治疗中添加evolocumab对患者的认知没有影响。

原始出处：

Baris G et al.Cognition After Lowering LDL-Cholesterol With Evolocumab.JACC.2020 May.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=903964, encodeId=379390396462, content=<a href='/topic/show?id=3323981903c' target=_blank style='color:#2F92EE;'>#降脂#</a>，用于<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>，还能改善认知！, beContent=null, objectType=article, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=98190, encryptionId=3323981903c, topicName=降脂), TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:19:07 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944654, encodeId=543f1944654f5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jan 15 01:46:34 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912353, encodeId=ac3719123530a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Mar 02 11:46:34 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854764, encodeId=26261854e642c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 14 14:46:34 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326610, encodeId=1942132661075, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426484, encodeId=ef35142648430, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=)]
    2020-12-01 智者为医08

    #降脂#，用于#动脉粥样硬化#，还能改善认知！

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=903964, encodeId=379390396462, content=<a href='/topic/show?id=3323981903c' target=_blank style='color:#2F92EE;'>#降脂#</a>，用于<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>，还能改善认知！, beContent=null, objectType=article, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=98190, encryptionId=3323981903c, topicName=降脂), TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:19:07 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944654, encodeId=543f1944654f5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jan 15 01:46:34 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912353, encodeId=ac3719123530a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Mar 02 11:46:34 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854764, encodeId=26261854e642c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 14 14:46:34 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326610, encodeId=1942132661075, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426484, encodeId=ef35142648430, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=)]
    2021-01-15 huangshifeng

    #粥样硬化#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=903964, encodeId=379390396462, content=<a href='/topic/show?id=3323981903c' target=_blank style='color:#2F92EE;'>#降脂#</a>，用于<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>，还能改善认知！, beContent=null, objectType=article, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=98190, encryptionId=3323981903c, topicName=降脂), TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:19:07 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944654, encodeId=543f1944654f5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jan 15 01:46:34 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912353, encodeId=ac3719123530a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Mar 02 11:46:34 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854764, encodeId=26261854e642c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 14 14:46:34 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326610, encodeId=1942132661075, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426484, encodeId=ef35142648430, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=)]
    2021-03-02 snf701207

    #mAb#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=903964, encodeId=379390396462, content=<a href='/topic/show?id=3323981903c' target=_blank style='color:#2F92EE;'>#降脂#</a>，用于<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>，还能改善认知！, beContent=null, objectType=article, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=98190, encryptionId=3323981903c, topicName=降脂), TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:19:07 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944654, encodeId=543f1944654f5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jan 15 01:46:34 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912353, encodeId=ac3719123530a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Mar 02 11:46:34 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854764, encodeId=26261854e642c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 14 14:46:34 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326610, encodeId=1942132661075, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426484, encodeId=ef35142648430, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=)]
    2021-03-14 hbwxf

    #JACC#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=903964, encodeId=379390396462, content=<a href='/topic/show?id=3323981903c' target=_blank style='color:#2F92EE;'>#降脂#</a>，用于<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>，还能改善认知！, beContent=null, objectType=article, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=98190, encryptionId=3323981903c, topicName=降脂), TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:19:07 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944654, encodeId=543f1944654f5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jan 15 01:46:34 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912353, encodeId=ac3719123530a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Mar 02 11:46:34 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854764, encodeId=26261854e642c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 14 14:46:34 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326610, encodeId=1942132661075, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426484, encodeId=ef35142648430, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=)]
    2020-05-09 12498568m50暂无昵称

    #ACC#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=903964, encodeId=379390396462, content=<a href='/topic/show?id=3323981903c' target=_blank style='color:#2F92EE;'>#降脂#</a>，用于<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>，还能改善认知！, beContent=null, objectType=article, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=98190, encryptionId=3323981903c, topicName=降脂), TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:19:07 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944654, encodeId=543f1944654f5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Jan 15 01:46:34 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912353, encodeId=ac3719123530a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Mar 02 11:46:34 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854764, encodeId=26261854e642c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 14 14:46:34 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326610, encodeId=1942132661075, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426484, encodeId=ef35142648430, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sat May 09 04:46:34 CST 2020, time=2020-05-09, status=1, ipAttribution=)]
    2020-05-09 ZGMFX25A

    #Evolocumab#

    0

相关资讯

盘点：JACC五月第1期研究一览

1. 心衰伴二尖瓣返流患者健康状态的变化与预后的相关性研究

NAT COMMUN：曲静/汤富酬/刘光慧合作揭示血管衰老的分子机制

至今为止，我们对衰老如何影响血管的细胞和分子成分，并导致心血管疾病的了解仍然有限。

JAHA：妊娠高血压对胎儿心脏发育会有明显影响

妊娠并发症如早产和胎儿生长受限与产前和产后心脏发育改变有关。本研究的目的旨在评估孕前高血压是否会胎儿心脏发育相关。

JACC：细胞粘附分子水平与心脏收缩功能呈相关性

E-选择素和细胞间粘附分子（ICAM）-1是内皮细胞活化的生物标志物，并且参与心衰伴保留型射血分数（HFpEF）的病理过程。本研究旨在评估E-选择素和ICAM-1与心功能亚临床改变的纵向相关性。

JAHA：肠道菌群代谢物TMAO与心血管死亡风险相关

三甲胺N-氧化物（TMAO）可能具有血栓的特性。本研究的目的旨在评估TMAO四分位数与主要心血管不良事件（MACE）的相关性，以及TMAO对替卡格雷疗效的影响。

JAHA：急性冠脉综合征症状存在性别差异

急性冠脉综合征（ACS）的及时诊断是治疗的关键，先前的研究表明患有ACS的女性与男性有不同的症状。本次荟萃分析的目的旨在评估ACS患者男女性的差异程度。